CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

NCT04176848 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

NETWORK

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: CFI-400945
DRUG: Durvalumab

Sponsor

Canadian Cancer Trials Group

Collaborators

[object Object]
[object Object]